Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial

Keyphrases

• Treatment Trials 100%
• Antiretroviral Therapy 100%
• Strategic Timing 100%
• Systemic Inflammation 100%
• Inflammation-coagulation 100%
• Clinical Risk 100%
• Inflammation Risk 100%
• Non-AIDS Comorbidities 66%
• CD4+ 33%
• Interleukin-6 33%
• D-dimer 33%
• CD4 Count 33%
• Antiretroviral Therapy Initiation 33%
• Inflammation 16%
• Risk Reduction 16%
• Disease-modifying Therapy 16%
• Biomarker Studies 16%
• Covariance Model 16%
• Age Groups 16%
• Event Risk 16%
• Nave 16%
• Gender Groups 16%
• Treatment Group 16%
• Cox Regression 16%
• Immediate Antiretroviral Therapy 16%
• Analysis of Covariance 16%
• AIDS Events 16%
• HIV Viral Load 16%
• Inflammation Injury 16%
• Vascular Injury Biomarkers 16%

Biochemistry, Genetics and Molecular Biology

• CD4 Lymphocyte Count 100%
• D-Dimer 100%
• CD4 100%
• Interleukin 6 100%
• RNA 50%
• Biomarker Study 50%
• Human Immunodeficiency Virus 50%
• Blood Plasma 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Biological Marker 100%
• Inflammation 100%
• D Dimer 28%
• Interleukin 6 28%
• HIV 14%
• Biomarker Study 14%
• Blood Vessel Injury 14%
• Disease 14%